Cargando…
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials
Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the first pharmacogenetic in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260990/ https://www.ncbi.nlm.nih.gov/pubmed/22048466 http://dx.doi.org/10.1038/npp.2011.232 |
_version_ | 1782221541158682624 |
---|---|
author | King, David P Paciga, Sara Pickering, Eve Benowitz, Neal L Bierut, Laura J Conti, David V Kaprio, Jaakko Lerman, Caryn Park, Peter W |
author_facet | King, David P Paciga, Sara Pickering, Eve Benowitz, Neal L Bierut, Laura J Conti, David V Kaprio, Jaakko Lerman, Caryn Park, Peter W |
author_sort | King, David P |
collection | PubMed |
description | Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and nicotine predict medication efficacy and adverse events. Subjects participated in randomized, double-blind, placebo-controlled smoking cessation clinical trials, comparing varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor, and placebo. Primary analysis included 1175 smokers of European ancestry, and 785 single nucleotide polymorphisms from 24 genes, representing 254 linkage disequilibrium (LD) bins (genes included nAChR subunits, additional varenicline-specific genes, and genes involved in nicotine or bupropion metabolism). For varenicline, continuous abstinence (weeks 9–12) was associated with multiple nAChR subunit genes (including CHRNB2, CHRNA5, and CHRNA4) (OR=1.76; 95% CI: 1.23–2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.78; 95% CI: 1.27–2.50) (p<0.001). Incidence of nausea was associated with several nAChR subunit genes (OR=0.50; 95% CI: 0.36–0.70) (p<0.0001) and time to relapse after quitting was associated with HTR3B (HR=1.97; 95% CI: 1.45–2.68) (p<0.0001). These data provide evidence for multiple genetic loci contributing to smoking cessation and therapeutic response. Different loci are associated with varenicline vs bupropion response, suggesting that additional research may identify clinically useful markers to guide treatment decisions. |
format | Online Article Text |
id | pubmed-3260990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32609902012-02-01 Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials King, David P Paciga, Sara Pickering, Eve Benowitz, Neal L Bierut, Laura J Conti, David V Kaprio, Jaakko Lerman, Caryn Park, Peter W Neuropsychopharmacology Original Article Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and nicotine predict medication efficacy and adverse events. Subjects participated in randomized, double-blind, placebo-controlled smoking cessation clinical trials, comparing varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor, and placebo. Primary analysis included 1175 smokers of European ancestry, and 785 single nucleotide polymorphisms from 24 genes, representing 254 linkage disequilibrium (LD) bins (genes included nAChR subunits, additional varenicline-specific genes, and genes involved in nicotine or bupropion metabolism). For varenicline, continuous abstinence (weeks 9–12) was associated with multiple nAChR subunit genes (including CHRNB2, CHRNA5, and CHRNA4) (OR=1.76; 95% CI: 1.23–2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.78; 95% CI: 1.27–2.50) (p<0.001). Incidence of nausea was associated with several nAChR subunit genes (OR=0.50; 95% CI: 0.36–0.70) (p<0.0001) and time to relapse after quitting was associated with HTR3B (HR=1.97; 95% CI: 1.45–2.68) (p<0.0001). These data provide evidence for multiple genetic loci contributing to smoking cessation and therapeutic response. Different loci are associated with varenicline vs bupropion response, suggesting that additional research may identify clinically useful markers to guide treatment decisions. Nature Publishing Group 2012-02 2011-11-02 /pmc/articles/PMC3260990/ /pubmed/22048466 http://dx.doi.org/10.1038/npp.2011.232 Text en Copyright © 2012 American College of Neuropsychopharmacology http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Original Article King, David P Paciga, Sara Pickering, Eve Benowitz, Neal L Bierut, Laura J Conti, David V Kaprio, Jaakko Lerman, Caryn Park, Peter W Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials |
title | Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials |
title_full | Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials |
title_fullStr | Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials |
title_full_unstemmed | Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials |
title_short | Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials |
title_sort | smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260990/ https://www.ncbi.nlm.nih.gov/pubmed/22048466 http://dx.doi.org/10.1038/npp.2011.232 |
work_keys_str_mv | AT kingdavidp smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT pacigasara smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT pickeringeve smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT benowitzneall smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT bierutlauraj smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT contidavidv smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT kapriojaakko smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT lermancaryn smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials AT parkpeterw smokingcessationpharmacogeneticsanalysisofvareniclineandbupropioninplacebocontrolledclinicaltrials |